Skip to main content
. Author manuscript; available in PMC: 2015 Aug 18.
Published in final edited form as: AIDS. 2012 Jul 31;26(12):1491–1500. doi: 10.1097/QAD.0b013e3283550b68

Fig. 3. Distribution of the probability of achieving viral suppression at 6 months for those patients who started on an EFV-based HAART or on an ATA/r-based HAART according to the percentiles of the propensity score for the entire study population stratified by history of injection drug use.

Fig. 3

ATA/r, atazanavir boosted with 400 mg/day or less of ritonavir; EFV, efavirenz.